Medtronic to add directors, form panels after Elliott takes large stake, WSJ reports

Medtronic announced it will add two new independent directors, John Groetelaars and Bill Jellison, to its board and form two new growth and operations committees, a move following Elliott Investment Management becoming a major shareholder. Concurrently, the medical-device maker raised its fiscal 2026 adjusted profit forecast to between $5.60 and $5.66 per share and reduced its estimated tariff impact to $185 million. Despite these governance changes and improved financial outlook, Medtronic shares declined 1.7% in premarket trading.

Analysis

Medtronic is undergoing a significant governance and strategic shift, heavily influenced by the new, large shareholder position taken by Elliott Investment Management. The company is adding two experienced med-tech executives, John Groetelaars and Bill Jellison, to its board and establishing two new committees focused on growth and operations. These committees have a clear mandate to pursue tuck-in M&A, R&D investments, potential divestitures, and to enhance earnings growth, signaling a direct response to activist pressure for value creation. Concurrent with these changes, Medtronic has issued positive financial updates, raising its fiscal 2026 adjusted profit forecast to between $5.60 and $5.66 per share and reducing its expected tariff impact for the year to $185 million. Despite these fundamentally positive developments, the company's shares registered a 1.7% decline in premarket trading, suggesting potential market skepticism or that the announced measures did not meet higher investor expectations. The company has set a clear timeline for accountability, with a planned investor day in mid-2026 to detail progress on these new initiatives.

Key Decisions for Investors

• Investors should view the activist-driven board and committee changes as a potential long-term catalyst for value creation, closely monitoring the new committees' progress on M&A and operational efficiency.
• Consider the disconnect between the improved fiscal 2026 profit guidance and the negative premarket stock reaction, which may present a buying opportunity if the market is overly pessimistic or a signal of deeper underlying concerns.
• Use the upcoming mid-2026 investor day as a key checkpoint to evaluate management's execution on its new strategic priorities before adjusting a long-term position.